



[Back](#)

# Tackling a disease on a global scale, the Global Parkinson's Genetics Program, GP2: A new generation of opportunities

[American Journal of Human Genetics](#) • Review • 2025 • DOI: 10.1016/j.ajhg.2025.07.014

[Blauwendraat, Cornelis](#)<sup>a,b,c</sup>; [Noyce, Alastair J.](#)<sup>d</sup>; [Mata, Ignacio F.](#)<sup>e</sup>; [Screven, Laurel A.](#)<sup>b</sup>; [Solle J.](#)<sup>f</sup>; [+7 authors](#)

<sup>a</sup>Coalition for Aligning Science, Chevy Chase, MD, United States

[Show all information](#)

0

Citations

[View PDF](#)

[Full text](#)

[Export](#)

[Save to list](#)

[Document](#)

[Impact](#)

[Cited by \(0\)](#)

[References \(83\)](#)

[Similar documents](#)

## Abstract

The need for more diversity in research is a widely recognized problem, especially in the genetics and genomics fields. While resolving this problem seems straightforward by recruiting and sequencing research participants from underrepresented populations, implementing an effort like this is complex operationally. Key considerations include ensuring equity, building capacity, and creating a sustainable research collective that works collaboratively to address local and global questions in research. Here, we provide a roadmap detailing how the Global Parkinson's Genetics Program (GP2) is tackling the lack of diversity in Parkinson disease (PD) genetics research and also reflect on 5 years of progress. GP2 aims to be a global hub facilitating subject recruitment, sample collection, data generation, harmonization, and sharing. It also acts as a centralized target discovery hub for PD genetics worldwide. The underlying tenets of GP2 center on transparency, the democratization of data and discovery, training and career support, providing (or generating)

actionable results, and creating a functional collective of PD researchers worldwide. GP2 is working with 275 research groups worldwide. There are data and samples from 265,000 subjects currently committed to the program as of May 2025. We discuss the lessons learned in this process and highlight what we view as the emerging opportunities that the program will aim to target over the next period. © 2025 The Author(s)

## Author keywords

global consortium; global genetics; Parkinson disease; precision medicine

## Indexed keywords

### EMTREE medical terms

genetics; genomics; human; Parkinson disease; personalized medicine; review; therapy

## Funding details

Details about financial support for research, including funding sources and grant numbers as provided in academic publications.

Funding sponsor	Funding number	Acronym
Parkinson's Foundation <a href="#">See opportunities by PF</a>		PF
American Parkinson Disease Association <a href="#">See opportunities by APDA</a>		APDA
Medical Research Council <a href="#">See opportunities by MRC</a>		MRC
National Institute for Health and Care Research <a href="#">See opportunities by NIHR</a>		NIHR
PSP Association <a href="#">See opportunities by PSPA</a>		PSPA

Funding sponsor	Funding number	Acronym
Parkinson's UK <a href="#">See opportunities</a> ↗		
Cure Parkinson's Trust <a href="#">See opportunities by CPT</a> ↗		CPT
National Institutes of Health <a href="#">See opportunities by USNIH</a> ↗	U01AG076482, 1R01NS112499, R01NS132437	USNIH
National Institutes of Health <a href="#">See opportunities by USNIH</a> ↗		USNIH
Michael J. Fox Foundation for Parkinson's Research <a href="#">See opportunities by MJFF</a> ↗	ASAP-GP2	MJFF
Michael J. Fox Foundation for Parkinson's Research <a href="#">See opportunities by MJFF</a> ↗		MJFF
Veterans Affairs Healthcare System	I01BX005978-01A1	

### Funding text

GP2 is funded by the ASAP initiative and implemented by The Michael J. Fox Foundation for Parkinson's Research. For a complete list of GP2 members, see <https://doi.org/10.5281/zenodo.15748014>. A.B.S. is supported by research grants from The Michael J. Fox Foundation for Parkinson's Research. H.R.M. is supported by research grants from Parkinson's UK, the Cure Parkinson's Trust, the PSP Association, the Medical Research Council, and The Michael J. Fox Foundation for Parkinson's Research. N.O. receives research grants from The Michael J. Fox Foundation for Parkinson's Research and the United Kingdom National Institute for Health and Care research (NIHR). I.F.M. receives funding from the National Institutes of Health (1R01NS112499, R01NS132437, and U01AG076482), the Veterans Affairs Healthcare System (I01BX005978-01A1), the American Parkinson Disease Association (APDA), the Parkinson's Foundation (PF), The Michael J. Fox Foundation (MJFF), and ASAP-GP2.

# Corresponding authors

Corresponding author

A.B. Singleton

---

Affiliation

Global Parkinson's Genetics Program, Chevy Chase, MD, United States

---

Email address

andy@gp2.org

---

© Copyright 2025 Elsevier B.V., All rights reserved.

## Abstract

Author keywords

Indexed keywords

Funding details

Corresponding authors

---

## About Scopus

[What is Scopus](#)

[Content coverage](#)

[Scopus blog](#)

[Scopus API](#)

[Privacy matters](#)

## Language

[日本語版を表示する](#)

[查看简体中文版本](#)

[查看繁體中文版本](#)

[Просмотр версии на русском языке](#)

## Customer Service

[Help](#)

[Tutorials](#)

ELSEVIER

[Terms and conditions](#) ↗ [Privacy policy](#) ↗ [Cookies settings](#)

All content on this site: Copyright © 2025 [Elsevier B.V.](#) ↗, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the [use of cookies](#) ↗.

